Description: Entera Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of orally delivered large molecule therapeutics for use in orphan indications and other areas with significant unmet medical need. The Company is initially applying its technology to develop an oral formulation of parathyroid hormone (PTH) for hypoparathyroidism (EB612) and osteoporosis (EB613).
Home Page: www.enterabio.com
ENTX Technical Analysis
Kiryat Hadassah Minrav Building
Jerusalem,
9112002
Israel
Phone:
972 2 532 7151
Officers
| Name | Title |
|---|---|
| Ms. Miranda J. Toledano M.B.A. | CEO & Director |
| Dr. Hillel Galitzer M.B.A., Ph.D. | Chief Operating Officer |
| Ms. Dana Yaacov-Garbeli CPA | CFO & Principal Financial Officer |
| Dr. Arthur C. Santora II, M.D., Ph.D. | Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.2615 |
| Price-to-Sales TTM: | 63.3717 |
| IPO Date: | 2018-06-28 |
| Fiscal Year End: | December |
| Full Time Employees: | 19 |